Lung cancer vaccine trial begins in UK

Benefits seemed very situational, especially for EGFR expression, but the future does seem to be personalized medicine, and this could be another piece to that puzzle.

https://aacrjournals.org/clincancerres/article/22/15/3782/79...

>> Survival benefit was significant (HR, 0.77; P = 0.036) in the per-protocol setting (patients receiving at least four vaccine doses): MST was 12.43 months for the vaccine arm versus 9.43 months for the control arm. MST was higher (14.66 months) for vaccinated patients with high EGF concentration at baseline.

Is this a joke? You are comparing two very different things.